We upgraded AAFP.org security on Dec. 7.
Account holders must create a new password. Previous passwords will no longer work.

brand logo

Am Fam Physician. 2025;112(6):692

Author disclosure: No relevant financial relationships.

CLINICAL QUESTION

What are the comparative benefits of the available treatments for acute migraine pain?

BOTTOM LINE

Adding a triptan (eg, sumatriptan) when a nonsteroidal anti-inflammatory drug (NSAID) or acetaminophen is ineffective will provide good symptom relief for most patients with acute migraine, with only a small risk of adverse effects. (Level of Evidence = 1a)

SYNOPSIS

A research librarian searched three databases, including Cochrane Central, and reference lists of identified studies. Investigators selected articles for inclusion. They augmented their findings with results from previous reviews. They identified 21 head-to-head studies and 165 placebo-controlled studies of treatment of acute migraine in adult outpatients that were published in English. Single reviewers extracted the data, and a second reviewer checked that data. Risk of bias was assessed independently by two reviewers. The reviewers did a pairwise meta-analysis when possible and conducted a network meta-analysis to get a complete picture. Triptan treatment was most effective for pain relief at 2 hours and freedom from pain for up to 48 hours after treatment. The combination of a triptan and NSAID is more effective than the triptan alone; adding acetaminophen to a triptan does not improve pain relief. Treatment with a triptan may be associated with a higher risk of adverse effects, although the risk is low. The analysis found no advantage of the newer ditan and gepant classes of migraine treatments and did not include older treatments such as metoclopramide, ergotamine, and prochlorperazine.

Already a member/subscriber?  Log In

Subscribe

From $180
  • Immediate, unlimited access to all AFP content
  • More than 125 CME credits/year
  • AAFP app access
  • Print delivery available
Subscribe

Issue Access

$59.95
  • Immediate, unlimited access to this issue's content
  • CME credits
  • AAFP app access
  • Print delivery available
Interested in AAFP membership?  Learn More

POEMs (patient-oriented evidence that matters) are provided by Essential Evidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.

For definitions of levels of evidence used in POEMs, see https://www.essentialevidenceplus.com/Home/Loe?show=Sort.

Primary Care Update, a free podcast focused on POEMs, is available on Apple Podcasts and Spotify.

This series is coordinated by Natasha J. Pyzocha, DO, contributing editor.

A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.

Continue Reading

More in AFP

Copyright © 2025 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.